key: cord-0782169-bti9aw8g
authors: Cathcart, Andrea L.; Havenar-Daughton, Colin; Lempp, Florian A.; Ma, Daphne; Schmid, Michael A.; Agostini, Maria L.; Guarino, Barbara; Di iulio, Julia; Rosen, Laura E.; Tucker, Heather; Dillen, Joshua; Subramanian, Sambhavi; Sloan, Barbara; Bianchi, Siro; Pinto, Dora; Saliba, Christian; Wojcechowskyj, Jason A; Noack, Julia; Zhou, Jiayi; Kaiser, Hannah; Chase, Arthur; Montiel-Ruiz, Martin; Dellota, Exequiel; Park, Arnold; Spreafico, Roberto; Sahakyan, Anna; Lauron, Elvin J.; Czudnochowski, Nadine; Cameroni, Elisabetta; Ledoux, Sarah; Werts, Adam; Colas, Christophe; Soriaga, Leah; Telenti, Amalio; Purcell, Lisa A.; Hwang, Seungmin; Snell, Gyorgy; Virgin, Herbert W.; Corti, Davide; Hebner, Christy M.
title: The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
date: 2021-08-06
journal: bioRxiv
DOI: 10.1101/2021.03.09.434607
sha: 7f855f9c58e7416c980c754703358670c52ba695
doc_id: 782169
cord_uid: bti9aw8g

VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 and VIR-7832 were derived from a parent antibody (S309) isolated from memory B cells of a 2003 severe acute respiratory syndrome coronavirus (SARS-CoV) survivor. Both mAbs contain an “LS” mutation in the Fc region to prolong serum half-life and potentially enhance distribution to the respiratory mucosa. In addition, VIR-7832 encodes an Fc GAALIE mutation that has been shown previously to evoke CD8+ T-cells in the context of an in vivo viral respiratory infection. VIR-7831 and VIR-7832 potently neutralize wild-type and variant authentic virus in vitro as well as variant pseudotyped viruses. In addition, they retain activity against monoclonal antibody resistance mutations conferring reduced susceptibility to currently authorized mAbs. The VIR-7831/VIR-7832 epitope does not overlap with mutational sites in current variants of concern and continues to be highly conserved among circulating sequences consistent with the high barrier to resistance observed in vitro. Furthermore, both mAbs can recruit effector mechanisms in vitro that may contribute to clinical efficacy via elimination of infected host cells. In vitro studies with these mAbs demonstrated no enhancement of infection. In a Syrian Golden hamster proof-of concept wildtype SARS-CoV-2 infection model, animals treated with VIR-7831 had less weight loss, and significantly decreased total viral load and infectious virus levels in the lung compared to a control mAb. Taken together, these data indicate that VIR-7831 and VIR-7832 are promising new agents in the fight against COVID-19.

The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 45 increase significantly with age, with 28.3% of COVID-19 patients over the age of 85 succumbing to donors. As expected, VIR-7832 induced NK cell-mediated ADCC in cells from donors expressing the 147 low-affinity F/F158 allele of FcγIIIa more efficiently than VIR-7831. These results were confirmed with 148 NK cells from a heterozygous donor (F/V 158). 149

The ability of VIR-7831 and VIR-7832 to facilitate ADCP by primary CD14 + monocytes was measured in 150 vitro by exposing freshly isolated human PBMCs to CHO-CoV-2-Spike cells that were pre-incubated 151 with antibody (Figure 2g) . VIR-7831, VIR-7832 and S309-LS induced similar levels of ADCP by CD14 + 152 monocytes. These results indicate that VIR-7831 and VIR-7832 have the potential to trigger ADCC and 153

Subneutralizing levels of VIR-7831 and VIR-7832 do not enhance virus uptake, replication or 155 cytokine production in vitro. One potential concern with any antibody therapeutic targeting a viral agent 156 is the possibility of antibody-dependent enhancement (ADE). ADE is an in vivo phenomenon in which 157 the presence of an antibody worsens disease. There are several in vitro assays that may provide plausible 158 correlates for ADE in vivo, though none of these have been proven relevant to COVID-19 as to date ADE 159 has not been observed in trials of monoclonal antibodies or plasma 13 7832 as a proxy for both antibodies. SARS-CoV-2 was subjected to 10 passages in the presence of 7832 at fixed concentrations of ~10x, 20x, 50x or 100x IC 50 (1, 2, 5, or 10 μg/mL) in VeroE6 cells. No 194 CPE was detected in wells passaged with antibody through 10 passages, while CPE was observed in the concentration of VIR-7832 through all 10 passages even at the lowest concentration tested. 197

As no viral breakthrough was observed in the fixed concentration resistance selection, a second method 198 was employed wherein SARS-CoV-2 virus was passaged in sub-IC 50 concentrations of antibody followed 199 by subsequent passaging in the presence of increasing concentrations of mAb in an attempt to force 200 resistance emergence (Supplemental Figure 3) . Passaging was performed in duplicate wells to account 201 for founder effects, and concentration increases for each well were based on CPE observations. Five 202 sequential passages were conducted using increasing concentrations of VIR-7832 at 0.5, 1, 2, 5 and ~10x 203 IC 50 (0.05, 0.1, 0.2, 0.5, 1 μg/mL; Supplemental Figure 3a), though no CPE was observed by passages 4 204 and 5 (0.5 and 1 μg/mL, respectively) indicating that variants originally selected at the lower 205 concentrations were either unfit or susceptible to the higher concentrations of antibody. To further assess 206 whether resistance mutations could be generated, selection was restarted using passage 3 virus generated 207 with ~2x IC50 (0.2 μg/mL) of VIR-7832 in duplicate wells at ~2x and ~5x IC50 (0.2, 0.5 μg/mL), 208 generating two passage lineages (Supplemental Figure 3b-c) . 209

Supernatants were evaluated for detectable virus at each passage by focus forming assay and cell 210 supernatants from viral passages containing detectable virus were tested in SARS-CoV-2 neutralization 211 assays to evaluate IC 50 shifts as a marker of reduced susceptibility (Supplemental Table 1 ). With the 212 exception of passage 8, modest fold changes were observed, with shifts in IC50 values ranging from 5.4-213 to 6.5-fold compared to the wild-type SARS-CoV-2 stock virus. In lineage 1, the passage 8 virus 214 displayed a >10-fold shift in IC50 (greater than highest concentration tested). Sequence analysis detected 215 an identical 4 amino acid insertion in the N-terminal domain (215-216insKLRS) and 5 amino acid 216 deletion in correspondence of the furin cleavage site (675-679del) in both lineages at all passages 217 sequenced, as well as the amino acid substitution E340A in lineage 1, and R682W, and V1128F in 218 lineage 2. The deletion at amino acids 675-679 has been previously described during passaging of SARS-219

CoV-2 in tissue culture suggesting enrichment to be a result of cell culture adaptation 44 while the 215-enriched with passaging (Supplemental Table 1 ) and enrichment of 675-679del and V1128F did not 222 profoundly alter the VIR-7832 IC50. However, appearance of the E340A variant at 98.7% did correlate 223 with a >10-fold shift in IC50 suggesting this variant may confer resistance. 224

To evaluate whether amino acid variants identified in the resistance selection conferred reduced 225 susceptibility to VIR-7831 and VIR-7832, neutralization of pseudotyped viruses encoding the S variants 226 was assessed (Supplemental Table 2 ). VIR-7831 and VIR-7832 neutralized R682W and V1128F SARS-227

CoV-2 pseudotyped virus spike variants with IC 50 values similar to wild type (< 2-fold change in IC50) 228

indicating that these variants do not alter susceptibility. In contrast, E340A conferred reduced 229 susceptibility to VIR-7831 and VIR-7832 (> 100-fold change in IC50) indicating that E340A is a VIR-230 7831/VIR-7832 monoclonal antibody resistance mutation (MARM). 231

As VIR-7831/VIR-7832 demonstrated a unique in vitro resistance profile, we investigated the potential 232 for cross-resistance to MARMs that confer reduced susceptibility to the authorized monoclonal antibodies 233 bamlanivimab, imdevimab and casirivimab 10,11,45-47 using pseudotyped virus. Notably, some of these 234 mutations are found in highly prevalent variants of concern 17,30,48 . VIR-7831 effectively neutralized 235 pseudotyped viruses expressing spike MARMs that alter bamlanivimab, casirivimab and/or imdevimab 236 activity (Table 3) . Fold changes in IC50 values compared to wild-type were <3-fold for 18/19 variants 237 tested. A modest 3.4-fold shift in the VIR-7831 IC50 was observed for the V445A variant that confers 238 reduced susceptibility to imdevimab. These data indicate that VIR-7831/VIR-7832 does not display cross-239 resistance with currently authorized mAbs and supports the potential combination use of VIR-7831/VIR-240 7832 with other mAb therapeutics. 241

The VIR-7831/VIR-7832 epitope is highly conserved among SARS-CoV-2 sequences. The parental 242 antibody of VIR-7831 and VIR-7832 (S309) binds to a highly conserved sarbecovirus epitope that is 243 potentially intolerant of variation. To investigate the current state of epitope conservation, >1,700,000 244 spike sequences from SARS-CoV-2 deposited in the GISAID database as of June 4, 2021 were examined 245 among currently available sequences for all positions including 16/23 amino acid positions that were 247 ≥99.99 conserved (Table 4) . 248 VIR-7831 activity against viral mutants carrying single substitutions in the epitope was assessed in 249 pseudotyped virus assays. VIR-7831 effectively neutralized epitope variants at most amino acid positions 250 tested ( Table 5) . A moderate shift in activity was observed for the K356T variant (5.9-fold shift in IC 50) . 251

Variants at two positions, E340 and P337, resulted in significant IC 50 shifts indicating reduced 252 susceptibility to VIR-7831. Moderate shifts in potency were observed for P337H and P337T variants 253 intraperitoneally at Day -1 (30, 5, 0.5 or 0.05 mg/kg) or Day -2 (15, 5, 0.5 or 0.05 mg/kg) prior to 263 intranasal SARS-CoV-2 inoculation (Figure 3a ). Using body weight as a marker of degree of clinical 264 disease, doses of ≥5mg/kg resulted in significantly reduced weight loss at Day 4 compared to controls. 265 (Figure 3b-e) . Significant decreases in lung viral load were also observed at ≥5mg/kg as measured by 266 RT-qPCR (Figures f-g) . Day 4 TCID 50 measurements indicated that antibody administered at ≥0.5 mg/kg 267 resulted in significantly lower levels of infectious virus in lung tissue compared to controls (Figure 3h-i) . 268

Notably, across these experiments, no enhancement of disease was observed in animals receiving 269

SGHmAb-no-LS based on changes in weight, viral RNA in the lungs, or TCID 50 infectious virus levels. and morbidity in SARS-CoV-2 challenged hamsters without signs of ADE at any dose tested. Notably, even at this stage of the pandemic, the VIR-7831/VIR-7832 epitope remains highly conserved 291 among available sequences of circulating virus with ≥99.8% conservation of epitope amino acids. This is 292 consistent with the value of the strategy used for isolation of monoclonal antibodies that neutralize both 293 SARS-CoV and SARS-CoV-2 based on the idea that these two virulent human viruses are positions P337 and E340 are present at very low levels among current sequences. That amino acids P337 296 and E340 remain ≥99.99% conserved at this stage of the pandemic indicates that variants at these 297 positions may confer disadvantageous effects on the virus, consistent with the conservation of this epitope 298 across the sarbecovirus family 21 . 299 Viral variants of concern for RBM-targeting mAbs are quickly spreading 53 . The vaccines presently being 300 deployed around the world generate high-titer neutralizing antibodies that target the S protein RBM. 301

Importantly, the RBM is highly immunodominant for responses to natural infection 54 . Vaccine-induced 302 and convalescent immunity may therefore potentially put further mutational pressure on the RBM 303 sequence to evade such antibody responses. In contrast, antibody responses overlapping with the VIR-304 7831/VIR-7832 epitope are limited after infection 54 , possibly because of the shielding effect of the highly 305 conserved N343 glycan. In this regard the epitope may face less vaccine-or infection-generated immune 306 pressure, potentially preserving this conserved epitope long-term. 307

Recent data have indicated that the cells used to generate live virus stocks and overexpression of 308 ACE2/TMPRSS2 in target cells used for assays can affect mAb activity in vitro 29,55 . The VIR-7831/VIR-309 7832 parental antibody S309 seems particularly sensitive to in vitro methods using ACE2 overexpressing 310 cells 55 . It is therefore notable that VIR-7831 displays significant efficacy in an in vivo proof-of-concept 311 SARS-CoV-2 infection experiment using hamsters despite the fact that patterns of engagement of hamster 312

FcRs by human IgG1 antibodies may not reflect patterns of human IgG1 antibodies with their cognate 313 human FcRs. These findings argue that in vitro data derived from such ACE2 and/or TMPRSS2 314 overexpression cell lines do not accurately reflect the in vivo antiviral capacity of tested mAbs. In vitro binding ELISA. For the ELISA assay, 96-well plates were coated with 100 µl/well recombinant 359 SARS-CoV2 RBD diluted in assay diluent (1% BSA/PBS) at a final concentration of 2 μg/mL and 360 incubated overnight at 4°C. Plates were washed three times with 300 µl/well wash buffer using an 361 automated washer. Assay diluent (100 µl/well) was added to block the plates and incubated for 1 hour at 362 room temperature (RT) with shaking. Assay diluent was removed, and plates washed three times with 363 wash buffer. Serial 1:3 dilutions of mAb (concentration range from 6 µg/mL to 0.33 ng/mL) in assay 364 diluent were dispensed at 100 µl/well and incubated 1 hour at RT with shaking, then washed three times 365 with wash buffer. The HRP-conjugated secondary antibody reagent (1:5,000 dilution in assay diluent) 366 was added to each well (100 µl/well) and incubated for 1 hour at RT with shaking. After three washes well and developed for 5 minutes at RT. The reaction was stopped with 100 µL/well 1M H2SO4 and the 369 OD was read immediately at 450 nm on a SpectraMax M5 Microplate reader. EC 50 Experiments were performed at 25°C, with the samples held at 15°C in the instrument prior to injection. 390

Measurement of Binding to Human Complement Protein C1q. Binding of VIR-7831 and VIR-7832 to 391 human complement was measured by biolayer interferometry (BLI) using an Octet Red96 instrument 7832 at 10 µg/ml for 10 minutes. The IgG-loaded sensors were then exposed to kinetics buffer containing 394 3 µg/ml of purified human C1q for 4 minutes, followed by a dissociation step in the same buffer for 395 additional 4 minutes. Association and dissociation profiles were measured in real time as changes in the 396 interference pattern. 37°C. In brief, plates were centrifuged for 4 minutes at 400 x g, and 35 µl of supernatant was transferred protocol, the absorbance at 490 nm and 650 nm was measured once every 2 minutes for 8 minutes, and 494 the slope of the kinetics curve was used as result. The percent specific lysis was determined by applying 495 the following formula: (specific release -spontaneous release) / (maximum release -spontaneous release) 496

x 100. HotStart ReadyMix) with primers 5' aattatcttggcaaaccacg-3' and 5' tgaggcttgtatcggtatcg-3'. 559

Amplification conditions included an initial 3 minutes at 95°C, followed by 28 cycles with 20 seconds at 560 98°C, 15 seconds at 62°C and 72°C for 2 minutes, with a final 4 minutes at 72°C. PCR products were 561 purified using AMPure XP beads following manufacturer's instructions. The size of the amplicon was 562 confirmed by analyzing 2 μL of PCR products using the Agilent D5000 ScreenTape System. Products 563 were quantified by analyzing 1 μL with the Quant-iT dsDNA High-Sensitivity Assay Kit. Twenty ng of 564 purified PCR product was used as input for library construction using the NEBNext Ultra II FS DNA 565 Library Prep kit following manufacturer's instructions. DNA fragmentation was performed for 13 566 construction, with a total of 6 PCR cycles. Libraries size was determined using the Agilent D1000 Animals were inoculated intranasally at Day 0 with 7.4x10 4 TCID50 with SARS-CoV-2 (isolate USA-586 WA1/2020). Animals were also weighed once daily in the morning beginning on study Day -10 and 587

continuing until the end of the study. Following euthanasia, RT-qPCR was performed on lung 588 homogenates using quantitative real-time PCR methods targeting the SARS-CoV-2 N gene and the 589 median tissue culture infections dose (TCID50) was determined per Lovelace internal methodology. Table 1 . VIR-7831 and VIR-7832 retain activity against S variants of concern in an authentic virus 775 system. Average fold change in VIR-7831 and VIR-7832 IC 50 compared to relative wild-type controls for 776 S variants tested in an authentic virus system. Data shown are averages of at least two independent 777 experiments. 778 Table 2 . VIR-7831 and VIR-7832 retain activity against S variants of concern in a pseudotyped virus 779 system. Average fold change in VIR-7831 and VIR-7832 IC 50 compared to relative wild-type controls for 780 S variants tested in a VSV/VeroE6 pseudotyped virus system. Data shown are averages of at least two 781 independent experiments. 782 Table 3 . VIR-7831 and VIR-7832 retain activity against variants that confer resistance to authorized 783 mAbs. Activity of VIR-7831 against variants conferring reduced susceptibility to bamlanivimab, 784 imdevimab or casirivimab in a VSV/VeroE6 pseudotyped virus system. The geometric mean of IC 50s and 785

shown. 787 Table 4 . The VIR-7831/VIR-7832 epitope is highly conserved. Conservation data comprising >1,700,000 788 sequences from the GISAID database and variants at each position are shown. Variants in bold were 789 tested in a pseudotyped virus assay. 790 Table 5 . Activity of VIR-7831 against epitope variants. VIR-7831/VIR-7832 epitope variants detected in 791 sequences from the GISAID database were tested in a VSV/VeroE6 pseudotyped virus system. The 

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease

Assessing the age specificity of infection fatality rates for COVID-19: 609 systematic review, meta-analysis, and public policy implications

Multi-organ impairment in low-risk individuals with long COVID

Psychological characteristics associated with COVID-19 vaccine hesitancy 614 and resistance in Ireland and the United Kingdom

COVID-19 Vaccination Hesitancy in the United States: A Rapid 616 National Assessment

High Rates of COVID-19 Vaccine Hesitancy and Its Association with 618

Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries

Emergence and rapid spread of a new severe acute respiratory syndrome-621 related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with 624 emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein -625 SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology -Virological

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage 630 in the UK defined by a novel set of spike mutations -SARS-CoV-2 coronavirus

Casirivimab and Imdevimab EUA Fact Sheet for Healthcare Providers

Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

Effect of Bamlanivimab as Monotherapy or in Combination With 642

Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-645 19

REGN-COV2, a Neutralizing Antibody Cocktail

Prospective mapping of viral mutations that escape antibodies used to treat 649 COVID-19

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to 651

Antibody Neutralization

Antibody potency, effector function, and combinations in protection and 653 therapy for SARS-CoV-2 infection in vivo

Human neutralizing antibodies against SARS-CoV-2 require intact Fc 655 effector functions and monocytes for optimal therapeutic protection

Fcγ Receptor Function and the Design of Vaccination 658 Strategies

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV 660 antibody

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV 662 antibody

Enhanced neonatal Fc receptor function improves protection against primate 664 SHIV infection

Enhanced antibody half-life improves in vivo activity

Safety and pharmacokinetics of the Fc-modified HIV-1 human 668 monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

immunity to viral respiratory infection

Antibodies targeting sialyl Lewis A mediate 673 tumor clearance through distinct effector pathways

SARS-CoV-2 variants show resistance to neutralization by many 677 monoclonal and serum-derived polyclonal antibodies

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and 680 serum-derived polyclonal antibodies

Structure and Function Analysis of an Antibody Recognizing All 682 Influenza A Subtypes

Broadly neutralizing hemagglutinin 684 stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

Both Neutralizing and Non-Neutralizing Human H7N9 Influenza 687

Vaccine-Induced Monoclonal Antibodies Confer Protection

Optimal activation of Fc-mediated effector functions by influenza virus 690 hemagglutinin antibodies requires two points of contact

Specificity and affinity of human Fcγ receptors and their polymorphic 693 variants for human IgG subclasses

Antibodies targeting sialyl Lewis A mediate 695 tumor clearance through distinct effector pathways

Development of a robust reporter-based ADCC assay with frozen, thaw-697 and-use cells to measure Fc effector function of therapeutic antibodies

A perspective on potential antibody-dependent enhancement of SARS-700

Update: CO VID-19 Convalescent Plasma in 702 20,000 Hospitalized Patients

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance 706 influenza virus respiratory disease

Antibody-dependent enhancement of influenza disease promoted by 708 increase in hemagglutinin stem flexibility and virus fusion kinetics

Tropism, replication competence, and innate immune responses of the 711 coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and 712 in-vitro cultures

Identification of Common Deletions in the Spike Protein of Severe Acute 714 Respiratory Syndrome Coronavirus 2

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational 716 escape seen with individual antibodies

Circulating SARS-CoV-2 spike N439K variants maintain fitness while 718 evading antibody-mediated immunity

Complete map of SARS-CoV-2 720 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with

Covid-19: The E484K mutation and the risks it poses

VIR-7831 for the Early Treatment of COVID-19 in Outpatients -Full Text View -724

A Study of Immune System Proteins in Participants With Mild to Moderate

Illness -Full Text View -ClinicalTrials.gov

Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate

the early treatment of COVID-19 | GSK

Covid-19: New coronavirus variant is identified in UK